Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2015

View Archived Issues

Corbus Pharmaceuticals receives IND clearance from FDA to begin phase II trials of Resunab

Canagliflozin provides greater reduction in A1C and body weight than sitagliptin

Phase I results reported on novel peptide deformylase inhibitor, IDP-73152 mesylate

HM-10560A found safe in growth hormone deficiency patients

AGTC files IND to study gene therapy for X-linked retinoschisis

CureVac patents new rabies vaccine

LG Life Sciences discloses necrosis and apoptosis inhibitors

Shanghai Bioduro Biologics patent describes FFAR1 agonists

Allergen completes series B financing round to advance drug development portfolio

Taiho Pharmaceutical divulges novel EGFR inhibitors

Toyama Chemical reports development of antifungal agents

BriaCell Therapeutics submits phase I/II protocol to the FDA

GlaxoSmithKline describes second-generation HIV-1 maturation inhibitor

Galectin Therapeutics to conduct phase II trial of GR-MD-02 in NASH

Thyroid hormone receptor activation induces white adipose tissue conversion

Kura Oncology enters into agreement with Janssen Pharmaceutica for tipifarnib

Neuralstem reports topline results from phase II NSI-566 trial

Endo makes proposal to acquire Salix

NIH grant supports RetroVirox's work in HIV

Evotec and Second Genome establish microbiome discovery and development collaboration

Novartis's LCZ-696 awarded priority review by Health Canada

Epizyme regains ex-Japanese rights to EPZ-6438 from Eisai

Meiji Seika Pharma discontinues development of ME-3301

AB Science reports results from phase Ib/II study of masitinib in triple-negative breast cancer

FDA accepts resubmitted NDA for daclatasvir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...